Navepegritide: first approval
Navepegritide is a C-type natriuretic peptide (CNP) prodrug developed by Ascendis Pharma for the treatment of achondroplasia and under investigation for hypochondroplasia. Given once…

Navepegritide is a C-type natriuretic peptide (CNP) prodrug developed by Ascendis Pharma for the treatment of achondroplasia and under investigation for hypochondroplasia. Given once weekly, navepegritide is designed to provide sustained release of, and continuous exposure to, active CNP — which is needed to counter overactive fibroblast growth factor receptor 3 signaling in achondroplasia — leading to improved growth velocity. Navepegritide recently received accelerated approval in the United States to increase linear growth in pediatric patients aged 2 years and older with achondroplasia and open epiphyses. This article summarizes the milestones in the development of navepegritide leading to this first approval for achondroplasia.
Read more: PMC
This article is for educational and informational purposes only and is not a substitute for advice, diagnosis or treatment by a physician or pharmacist.
Original Persian text: meshcutpharmed.com
Related posts

UK regulator bans stem-cell treatment ads as “misleading”
The UK advertising watchdog has banned ads from four companies promoting stem-cell treatment for autism in children, ruling them misleading.
Read more
Is heart damage from anabolic steroids reversible?
According to a longitudinal study with 6 to 8 years of follow-up, long-term use of anabolic-androgenic steroids (AAS) in male strength athletes is associated with persistent cardiac…
Read more
Fibroid drug relugolix may act as a contraceptive
According to research presented at the American Society for Reproductive Medicine (ASRM) 2026 meeting, relugolix (Orgovyx) — used in combination with estradiol and norethindrone acetate to…
Read more